Iopromide (Ultravist, BAY86-4877)
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
20
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Contrast Medium
Conditions
Contrast Medium
Trial Timeline
Oct 12, 2018 → Feb 14, 2019
NCT ID
NCT03622801About Iopromide (Ultravist, BAY86-4877)
Iopromide (Ultravist, BAY86-4877) is a pre-clinical stage product being developed by Bayer for Contrast Medium. The current trial status is completed. This product is registered under clinical trial identifier NCT03622801. Target conditions include Contrast Medium.
Hype Score Breakdown
Clinical
5
Activity
2
Company
7
Novelty
2
Community
1
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03622801 | Pre-clinical | Completed |
| NCT02840903 | Pre-clinical | Completed |
| NCT01415414 | Pre-clinical | Completed |
| NCT01206257 | Pre-clinical | Completed |
Competing Products
11 competing products in Contrast Medium
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| HRS-9231 + Gadobutrol | Jiangsu Hengrui Medicine | Phase 2 | 52 |
| Gadoquatrane (BAY1747846) | Bayer | Phase 3 | 74 |
| GBCAs | Bayer | Pre-clinical | 20 |
| BAY1747846 | Bayer | Phase 1 | 30 |
| Gadoquatrane (BAY1747846) + Gadobutrol + Gadoterate meglumine + Gadoteridol | Bayer | Phase 3 | 74 |
| Gadoquatrane (BAY1747846) + Gadobutrol + Gadoterate meglumine + Gadoteridol | Bayer | Phase 3 | 74 |
| Gadoxetic acid disodium (Primovist, BAY86-4873) | Bayer | Approved | 82 |
| BAY1747846 + Matching placebo | Bayer | Phase 1 | 30 |
| Gadoquatrane (BAY1747846) 0.03 mmol Gd/kg + Gadoquatrane (BAY1747846) 0.1 mmol Gd/kg + Matching placebo | Bayer | Phase 1 | 30 |
| Gadobutrol (Gadavist/Gadovist, BAY86-4875) | Bayer | Pre-clinical | 20 |
| Magnevist + Dotarem + Gadovist | Guerbet | Pre-clinical | 15 |